CHANGCHUN, China & LOS ANGELES---China Yongxin Pharmaceuticals Inc., a leading manufacturer, distributor and retailer of pharmaceuticals in Northeastern China, today announced that it has completed its previously announced reverse merger with Nutradyne Group, Inc. and, to better reflect the Company's true business, has changed its corporate name to China Yongxin Pharmaceuticals Inc. as well as its ticker symbol to ``OTCBB: CYXN.''
56071
China Yongxin Pharmaceuticals Inc. completes reverse merger;
10363
NuVasive to acquire Osteocel biologics business from Osiris Therapeutics
80180
Novartis buys rights to new antibiotic
62644
Dietary supplements illegally labeled:
155554
CNOOC Limited completes acquisition of Nexen Inc.
126233
Astex achieves milestones in drug discovery collaboration
173696
Chinese rebar producers cut prices by adding boron
98276
Sanofi to expand in China
106973
Questcor Pharmaceuticals acquires rights to Synacthen®
80620
Debix announces AllClear ID:
133910
Thermo Fisher Scientific plans for new manufacturing facility in China
119930
Drug maker Mylan to move to Nasdaq
66481
Spectrum Pharmaceuticals to acquire Allos Therapeutics:
165699
Pharmaceutical markets in India
97372
Mitrix changes name to Amitive;
34605
Eli Lilly acquires SGX Pharmaceuticals
65487
Amgen selling Japanese rights to some drugs